Chemotherapy for advanced lung cancer: When to expect a response

David Eric Midthun, James R. Jett

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Chemotherapy has been shown to lengthen survival in patients with stage IIIA NSCLC when used preoperatively (major response rates of 50% to 75%). Chemotherapy in combination with radiation for unresectable stage IIIA or IIIB disease has also improved survival rates. Major response rates of 10% to 30% are reported in cases of stage IV disease. Chemotherapy is now remarkably successful in achieving response in patients with limited SCLC, and 5-year survival rates as high as 10% to 15% are reported. Further increases in the 5-year survival rate will depend on improved chemotherapeutic treatment of nonsurgical disease. Research in the 1990s has presented a number of new chemotherapeutic agents with promising activity against this recalcitrant disease.

Original languageEnglish (US)
JournalPostgraduate Medicine
Volume101
Issue number3
StatePublished - Mar 1997

Fingerprint

Lung Neoplasms
Drug Therapy
Survival Rate
Combination Drug Therapy
Radiation
Survival
Research
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Chemotherapy for advanced lung cancer : When to expect a response. / Midthun, David Eric; Jett, James R.

In: Postgraduate Medicine, Vol. 101, No. 3, 03.1997.

Research output: Contribution to journalArticle

@article{85b29b169c574eb587bea64fae98c73b,
title = "Chemotherapy for advanced lung cancer: When to expect a response",
abstract = "Chemotherapy has been shown to lengthen survival in patients with stage IIIA NSCLC when used preoperatively (major response rates of 50{\%} to 75{\%}). Chemotherapy in combination with radiation for unresectable stage IIIA or IIIB disease has also improved survival rates. Major response rates of 10{\%} to 30{\%} are reported in cases of stage IV disease. Chemotherapy is now remarkably successful in achieving response in patients with limited SCLC, and 5-year survival rates as high as 10{\%} to 15{\%} are reported. Further increases in the 5-year survival rate will depend on improved chemotherapeutic treatment of nonsurgical disease. Research in the 1990s has presented a number of new chemotherapeutic agents with promising activity against this recalcitrant disease.",
author = "Midthun, {David Eric} and Jett, {James R.}",
year = "1997",
month = "3",
language = "English (US)",
volume = "101",
journal = "Postgraduate Medicine",
issn = "0032-5481",
publisher = "Medquest Communications LLC",
number = "3",

}

TY - JOUR

T1 - Chemotherapy for advanced lung cancer

T2 - When to expect a response

AU - Midthun, David Eric

AU - Jett, James R.

PY - 1997/3

Y1 - 1997/3

N2 - Chemotherapy has been shown to lengthen survival in patients with stage IIIA NSCLC when used preoperatively (major response rates of 50% to 75%). Chemotherapy in combination with radiation for unresectable stage IIIA or IIIB disease has also improved survival rates. Major response rates of 10% to 30% are reported in cases of stage IV disease. Chemotherapy is now remarkably successful in achieving response in patients with limited SCLC, and 5-year survival rates as high as 10% to 15% are reported. Further increases in the 5-year survival rate will depend on improved chemotherapeutic treatment of nonsurgical disease. Research in the 1990s has presented a number of new chemotherapeutic agents with promising activity against this recalcitrant disease.

AB - Chemotherapy has been shown to lengthen survival in patients with stage IIIA NSCLC when used preoperatively (major response rates of 50% to 75%). Chemotherapy in combination with radiation for unresectable stage IIIA or IIIB disease has also improved survival rates. Major response rates of 10% to 30% are reported in cases of stage IV disease. Chemotherapy is now remarkably successful in achieving response in patients with limited SCLC, and 5-year survival rates as high as 10% to 15% are reported. Further increases in the 5-year survival rate will depend on improved chemotherapeutic treatment of nonsurgical disease. Research in the 1990s has presented a number of new chemotherapeutic agents with promising activity against this recalcitrant disease.

UR - http://www.scopus.com/inward/record.url?scp=1842411294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842411294&partnerID=8YFLogxK

M3 - Article

C2 - 9074558

AN - SCOPUS:1842411294

VL - 101

JO - Postgraduate Medicine

JF - Postgraduate Medicine

SN - 0032-5481

IS - 3

ER -